Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer’s Disease.

por jcdadm.website | ago 1, 2017 | Publication

Dadar M, Pascoal TA, Manitsirikul S, Misquitta K, Fonov VS, Tartaglia MC, Breitner J, Rosa-Neto P, Carmichael OT, Decarli C, Collins DL. IEEE Trans Med Imaging. 2017 Aug;36(8):1758-1768. doi: 10.1109/TMI.2017.2693978. Epub 2017 Apr 12.

Synergistic interaction between amyloid and tau predicts the progression to dementia.

por jcdadm.website | jun 1, 2017 | Publication

Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S, Beaudry T, Kang MS, Soucy JP, Labbe A, Gauthier S, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement. 2017 Jun;13(6):644-653. doi: 10.1016/j.jalz.2016.11.005. Epub...

Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.

por jcdadm.website | maio 9, 2017 | Publication

Ng KP, Pascoal TA, Mathotaarachchi S, Chung CO, Benedet AL, Shin M, Kang MS, Li X, Ba M, Kandiah N, Rosa-Neto P, Gauthier S; Alzheimer’s Disease Neuroimaging Initiative. Neurology. 2017 May 9;88(19):1814-1821. doi: 10.1212/WNL.0000000000003916. Epub 2017 Apr...

Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.

por jcdadm.website | mar 31, 2017 | Publication

Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, Guiot MC, Guo Q, Harada R, Comley RA, Massarweh G, Soucy JP, Okamura N, Gauthier S, Rosa-Neto P. Alzheimers Res Ther. 2017 Mar 31;9(1):25. doi: 10.1186/s13195-017-0253-y.

The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer’s disease from the Alzheimer’s Disease Neuroimaging Initiative database.

por jcdadm.website | fev 9, 2017 | Publication

Ba M, Li X, Ng KP, Pascoal TA, Mathotaarachchi S, Rosa-Neto P, Gauthier S; Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement (N Y). 2017 Feb 9;3(1):107-113. doi: 10.1016/j.trci.2016.12.005. eCollection 2017 Jan.

Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer’s disease.

por jcdadm.website | fev 1, 2017 | Publication

Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung CO, Shin M, Wang S, Beaudry T, Kang MS, Soucy JP, Labbe A, Gauthier S, Rosa-Neto P. Mol Psychiatry. 2017 Feb;22(2):306-311. doi: 10.1038/mp.2016.37. Epub 2016 Mar 29.